Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

BACKGROUND: The purpose of this study was to evaluate the post-marketing safety and effectiveness of aripiprazole in treating irritability in pediatric patients (6–17 years) with autism spectrum disorder (ASD) in actual clinical sites of Japan. METHODS: In this post-marketing surveillance, patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Yuna, Yamamura, Kayo, Takayama, Tomoyo, Fukuta, Yasuhiko, Aoki, Kazuo, Mikami, Katsunaka, Tomoda, Akemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061053/
https://www.ncbi.nlm.nih.gov/pubmed/33888067
http://dx.doi.org/10.1186/s12888-021-03201-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061053/
https://www.ncbi.nlm.nih.gov/pubmed/33888067
http://dx.doi.org/10.1186/s12888-021-03201-6

Ejemplares similares